Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases
A Prospective Study of Hyperthermia Combined With Autologous Adoptive Cellular Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases
Sponsor: Capital Medical University
A PHASE1/PHASE2 clinical study on Abdominal Cancer and Cancer, this trial is completed. The trial is conducted by Capital Medical University and has accumulated 8 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Status: Unknown Status → Completed
-
Sep 2022 — Mar 2024 [monthly]
Unknown Status PHASE1_PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Sep 2022 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 3 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2019 — Aug 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2018 — Apr 2019 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Mar 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Capital Medical University
For direct contact, visit the study record on ClinicalTrials.gov .